Q-omics provides the consensus-scored DCDC2B profile across patient tissues and cancer cell-line models. DCDC2B expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, DCDC2B is differentially expressed in 11, with the highest sampling consensus in LUSC. Additionally, DCDC2B RNA expression shows 20,399 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, LUSC, and THYM as cancer lineages where DCDC2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DCDC2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DCDC2B survival associations across molecular data types. DCDC2B RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DCDC2B RNA expression–survival associations across cancer types. High DCDC2B expression shows unfavorable associations in LGG, ACC and UVM, but favorable associations in HNSC, BRCA and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for DCDC2B RNA expression.
This table summarizes DCDC2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in LUSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for DCDC2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DCDC2B shows lower tumor expression in LUSC, LUAD and KICH and higher tumor expression in COAD, CHOL and KIRC. The LUSC box plot shows higher DCDC2B RNA expression in normal versus tumor tissue (log2 FC = −1.522, t-test p < 0.001).
This table shows molecular features associated with DCDC2B in patient tissues and cancer cell lines. In patient samples, DCDC2B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, DCDC2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and SOFT_TISSUE.
